Discoid lupus erythematosus
ICD-10 L93.0 · ICD-11 EB51.0

Treatment of Discoid Lupus Erythematosus with Severe or Widespread Skin Lesions, or Risk of Scarring and Systemic Progression

Clinical Scenario

This protocol addresses patients with severe or widespread skin lesions of discoid lupus erythematosus, or those at risk of permanent scarring or progression to systemic disease, who are not pregnant and not breastfeeding.

Why This Situation Requires a Structured Approach

Severe or widespread cutaneous involvement carries a heightened risk of irreversible scarring and systemic extension. Antimalarials are recommended as first-line long-term systemic treatment in this population — particularly in patients with the risk of scarring and development of systemic disease. Active severe or widespread lesions additionally call for systemic corticosteroids as a first-line measure alongside antimalarials.

Treatment Approach — Partial Overview

The recommended regimen combines topical therapy with long-term systemic antimalarial treatment. For severe or widespread active disease, systemic corticosteroid therapy is incorporated as an additional first-line component alongside antimalarials, with a planned taper once disease is controlled.

Drug selection, dosage guidance, sequencing, and the full algorithm are available in the complete protocol below.

Instant Access to Structured Evidence-Based Regimens

References

  1. We recommend antimalarials as first-line and long-term systemic treatment in all CLE patients with severe or widespread skin lesions, in particular in patients with the risk of scarring and development of systemic disease.
  2. In severe or widespread active CLE lesions, systemic corticosteroids are recommended as first-line treatment in addition to antimalarials.
  3. We recommend topical corticosteroids as first-line treatment for a time limited up to some weeks in all CLE lesions.
  4. In patients with widespread disease and/or the risk of scarring, we recommend concomitant treatment with antimalarials.
  5. We recommend to taper the dose of systemic corticosteroids to a minimum with the aim to discontinue the administration, as soon as the disease being treated is under control.
View source ↗